ENDRA Life Sciences (NDRA) Equity Average (2017 - 2026)

ENDRA Life Sciences has disclosed Equity Average across 10 years of filings, most recently posting $2.0 million for Q1 2026.

• In Q1 2026, Equity Average fell 6.17% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $2.0 million (down 6.17% YoY), while the FY2025 annual figure was $2.4 million, down 41.35% from the prior year.
• Equity Average climbed to $2.0 million in Q1 2026, from $1.2 million in the prior quarter.
• Over the last five years, Equity Average for NDRA reached as high as $11.8 million in Q3 2022 and fell as low as $822265.5 in Q3 2025.
• The 5-year median for Equity Average is $5.7 million (2023), against an average of $5.6 million.
• Annual changes were most pronounced in 2024 — Equity Average grew 28.63% — and 2025, when it plunged 89.46%.
• A 5-year view of Equity Average shows it stood at $8.7 million in 2022, then tumbled by 37.64% to $5.4 million in 2023, then dropped by 15.57% to $4.6 million in 2024, then slumped by 73.47% to $1.2 million in 2025, then soared by 66.44% to $2.0 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $2.0 million, $1.2 million, and $822265.5 for Q1 2026, Q4 2025, and Q3 2025 respectively.